Suven Life Sciences secures product patents in Israel, Japan, New Zealand, Sri Lanka


Equity tips:-

The granted claims of the patents include the class of selective 5-HT4 and M1 PAM compounds.





Suven Life Sciences in its filing to the exchanges informed that the company received product patent from Israel, Japan, New Zealand, and Sri Lanka corresponding to the New Chemical Entities for the treatment of disorders associated with Neurodegenerative diseases and patents are valid through 2036 and 2029, respectively.


The granted claims of the patents include the class of selective 5-HT4 and M1 PAM compounds, the company said in a press note after markets hours to the exchanges on Wednesday.



The patents are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Pain, Parkinson Disease and Schizophrenia etc, the company added.



Suven Life Sciences Ltd's share price ended at Rs255.40, down by Rs6.65 or 2.54%, from its previous close of Rs262.05 on the BSE.
The scrip opened at Rs263.95 and touched a high and low of Rs263.95 and Rs254.20, respectively. A total of, 2,00,102 (NSE+BSE) shares have traded on the counter. The current market cap of the company is Rs3,250.79cr.

We provide free profit calls for EQUITY,Forex & COMMODITY tips.If you want more information regarding the Stock cash tips, Nifty tips, Commodity tips, Equity tips,forex tips missed call @ 8966834895 

Comments

Post a Comment

Popular posts from this blog

Asian markets trade higher; Shanghai Composite up 1.5%

Asian stocks trade mixed; Nikkei 225 up ~1%

SGX Nifty indicates a flat opening for markets